AstraZeneca Pharma India Ltd to launch Tremelimumab

AstraZeneca Pharma India Limited will launch Tremelimumab (Imjudo) in October 2024 in India.

Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC).

The company received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Tremelimumab (Imjudo) Concentrate for solution for infusion 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations in single dose vials) administered through intravenous route on June 1, 2023.

Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 6728.00 as compared to the previous close of Rs. 6703.00. The total number of shares traded during the day was 327 in over 188 trades.

The stock hit an intraday high of Rs. 6786.00 and intraday low of 6550.00. The net turnover during the day was Rs. 2183134.00.

Source : Equity Bulls

Keywords

AstraZenecaPharmaIndia INE203A01020 Pharmaceuticals NewProductLaunch Tremelimumab